Обзор исследований с амлодипиномпри артериальной гипертонии
Обзор исследований с амлодипиномпри артериальной гипертонии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Kloner RA, Sowers JR, DiBona GF et al. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1996; 77: 713–22.
2.Kloner RA, Weinberger M, Pool JL et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am J Cardiol 2001; 87: 727–31.
3. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.
4. Sowers JR. Comorbidity of hypertension and diabetes: the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). Am J Cardiol 1998; 82: 15R–9R.
5. Dahlof B, Lindholm LH, Carney S et al. Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. J Hypertens 1997; 15: 1327–35.
6. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001; 285: 2719–28.
7. Wright JT, Bakris G, Greene T et al. Effect of blood pressure lovering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 2002; 288: 2421–31.
8. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–28.
9. Pitt B, Byington RP, Furberg CD et al. Effect of amljdipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
10. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–25.
11. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the EUROPEAN Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
12. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981–97.
13. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with Valsartan- or Amlodipine-based regimens: VALUE, a randomized trial. Lancet 2004; 363: 2022–31.
14.Costanzo P, Perrone-Filardi P, Petretta M et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175 634 patients. J Hypertens 2009; 27: 1136–51.
2.Kloner RA, Weinberger M, Pool JL et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am J Cardiol 2001; 87: 727–31.
3. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.
4. Sowers JR. Comorbidity of hypertension and diabetes: the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). Am J Cardiol 1998; 82: 15R–9R.
5. Dahlof B, Lindholm LH, Carney S et al. Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. J Hypertens 1997; 15: 1327–35.
6. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001; 285: 2719–28.
7. Wright JT, Bakris G, Greene T et al. Effect of blood pressure lovering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 2002; 288: 2421–31.
8. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–28.
9. Pitt B, Byington RP, Furberg CD et al. Effect of amljdipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
10. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–25.
11. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the EUROPEAN Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
12. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981–97.
13. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with Valsartan- or Amlodipine-based regimens: VALUE, a randomized trial. Lancet 2004; 363: 2022–31.
14.Costanzo P, Perrone-Filardi P, Petretta M et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175 634 patients. J Hypertens 2009; 27: 1136–51.
Авторы
А.А.Упницкий
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.